Abstract
Background
Essential hypertension is one of the main risk factors for the development of coronary artery disease (CAD). Hypertension causes endothelial dysfunction which is considered an early sign for the development of CAD. Positron emission tomography is a non-invasive imaging technique that measures myocardial blood flow (MBF), allowing us to identify patients with endothelial dysfunction.
Methods and Results
19 patients without comorbidities recently diagnosed hypertensive, as well as 21 healthy volunteers were studied. A three-phase (rest, cold pressor test, and adenosine-induced hyperemia) 13N-ammonia PET was performed, and MBF was measured. Endothelial-Dependent Vasodilation Index, ΔMBF, and coronary flow reserve (CFR) were calculated for each patient. Hypertensive patients had a significantly higher systolic and diastolic blood pressures compared with the control group (134.6 ± 11.7/86.4 ± 10.6 mm Hg and 106.0 ± 11.8/71.4 ± 6.6 mm Hg, respectively, P < .001). The ENDEVI (1.28 ± 0.26 vs 1.79 ± 0.30, P < .001), the ΔMBF (0.81 ± 0.50 vs 0.25 ± 0.21, P < .001) and the CFR (2.18 ± 0.88 vs 3.17 ± 0.68, P = .001) were significantly lower in the hypertensive patients compared to the control group, 84% of the former group had endothelial dysfunction i.e., ENDEVI < 1.5 and 58% had vasomotor abnormalities, i.e., CFR < 2.5.
Conclusions
In this study, we showed that recently diagnosed hypertensive patients have coronary endothelial dysfunction and vasomotor disturbances which are early signs for the development of CAD.
Similar content being viewed by others
References
Olaiz-Fernández G, Rivera-Dommarco J, Shamah-Levy T, Rojas R, Villalpando-Hernández S, Hernández-Avila M, et al. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca: Instituto Nacional de Salud Pública; 2006.
Stevens G, Dias RH, Thomas KJA, Rivera JA, Carvalho N, Barquera S, et al. Characterizing the epidemiological transition in Mexico: National and subnational burden of diseases, injuries, and risk factors. PLoS Med 2008;5:e125. doi:10.1371/journal.pmed.0050125.
Prior JO, Quinones MJ, Hernandez-Pampaloni M, Facta A, Schindler T, Sayre J, et al. Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation 2005;111:2291-8.
Guethlin M, Kasel AM, Coppenrath K, Ziegler S, Delius W, Schwaiger M. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation 1999;99:475-81.
Czernin J, Sun K, Brunken R, Bottcher M, Phelps M, Schelbert H. Effect of acute and long-term smoking on myocardial blood flow and flow reserve. Circulation 1995;91:2891-7.
Alexánderson E, Ochoa JM, Calleja R, Juárez-Rojas JG, Prior JO, Jácome R, et al. Endothelial dysfunction in systemic lupus erythematosus: Evaluation with 13N-ammonia PET. J Nucl Med 2010;51:1-5.
Alexánderson E, Cruz P, Vargas A, Meave A, Ricalde E, Talayero JA, et al. Endothelial dysfunction in patients with antiphospholipid syndrome assessed with positron emission tomography. J Nucl Cardiol 2007;14:566-72.
Anderson T. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999;34:631-8.
Higuchi T, Abletshauser C, Nekolla SG, Schwaiger M, Bengel FM. Effect of the angiotensin receptor blocker Valsartan on coronary microvascular flow reserve in moderately hypertensive patients with stable coronary artery disease. Microcirculation 2007;14:805-12.
Sitia S, Tomasoni L, Atzeni F, Ambrosio G, Cordiano C, Catapano A, et al. From endothelial dysfunction to atherosclerosis. Autimmun Rev 2010;9:830-4.
Kasprzak J, Klosinska M, Drozdz J. Clinical aspects of assessment of endothelial function. Pharmacol Rep 2006;58:33-40.
Vanhoutte P. Endothelial dysfunction: The first step towards arteriosclerosis. Circ J 2009;73:595-601.
Mittra E, Quon A. Positron emission tomography/computed tomography: The current technology and applications. Radiol Clin N Am 2009;47:147-60.
Schelbert H. Quantification of myocardial blood flow: What is the clinical role? Cardiol Clin 2009;27:277-89.
Lenfant C, Chobanian AV, Jones DW, Roccella EJ, Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC 7). Hypertension 2003;42:1206.
Jonsson C, Odh R, Schnell PO, Larsson SA. A comparison of the imaging properties of a 3-and 4-ring biograph PET scanner using a novel extended NEMA phantom. IEE Nucl Sci Symp Conf Rec 2007;4:2865-7.
Townsend D, Jakoby B, Long M, Carr C, Hubner K, Guglielmo C, et al. Performance and clinical workflow of a new combined PET/CT scanner. J Nucl Med 2007;48:437.
Büther F, Dawood M, Stegger L, Dawood M, Stegger L, Schober O, et al. List mode-driven cardiac and respiratory gating in PET. J Nucl Med 2009;50:674-81.
Di Carli MF, Dorbala S, Meserve J, El Fakhiri G, Sitek A, Moore SC. Clinical myocardial perfusion PET/CT. J Nucl Med 2007;48:783-93.
Slomka PJ, Le Meunier L, Hayes SW, Acampa W, Oba M, Haemer G, et al. Comparison of myocardial perfusion 82Rb PET performed with CT- and transmission CT-based attenuation correction. J Nucl Med 2008;49:1992-8.
Prior J, Schindler T, Facta A, Hernández-Pampaloni M, Campisi R, Dahlborn M, et al. Determinants of myocardial blood flow response to cold pressor testing and pharmacologic vasodilation in healthy humans. Eur J Nucl Med Mol Imaging 2007;34:20-7.
Nitzsche EU, Choi Y, Czernin J, Koh C, Huang SC, Schelbert H. Noninvasive quantification of myocardial blood flow in humans: A direct comparison of the [13N] ammonia and the [15O]water techniques. Circulation 1996;93:2000-6.
Kuhle WG, Porenta G, Huang SC, Buxton D, Gambhir SS, Hansen H, et al. Quantification of regional myocardial blood flow using [13N]ammonia and reoriented dynamic positron emission tomographic imaging. Circulation 1992;86:1004-17.
Schindler TH, Nitzsche E, Olschewski M, Brink I, Mix M, Prior J, et al. PET-measured responses of MBF to cold pressor testing correlate with indices of coronary vasomotion on quantitative coronary angiography. J Nucl Med 2004;45:419-28.
Alexánderson E, Ricalde A, Estrada J, Alexánderson EG, Meave A. Evaluation of coronary flow by means of PET in the Mexican population without coronary artery disease. Arch Cardiol Mex 2005;75:23-8.
Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 2000;87:840-4.
Xu S, Touyz RM. Reactive oxygen species and vascular remodelling in hypertension: Still alive. Can J Cardiol 2006;22:947-51.
Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species and hypertension. Diabetes Care 2008;31:S170-80.
Papaharalambus CA, Griendling KK. Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc Med 2007;17:48-54.
Lassègue B, Griendling KK. NADPH oxidases: Functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol 2010;30:653-61.
Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;15:1916-23.
Alderman M, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324:1098-104.
Antony I, Nitenberg A, Foult JM, Aptecar E. Coronary vasodilator reserve in untreated and treated hypertensive patients with and without left ventricular hypertrophy. J Am Coll Cardiol 1993;22:514-20.
Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009;32:314-21.
Laine H, Raitakari O, Niinikoski H, Pitkanen O, Iida H, Viikari J, et al. Early impairment of coronary flow reserve in young men with borderline hypertension. J Am Coll Cardiol 1998;32:147-53.
Masuda D, Nohara R, Tamaki N, Hosokawa R, Inada H, Hikai T, et al. Evaluation of coronary blood flow reserve by 13N-NH3 positron emission computed tomography (PET) with dipyridamole in the treatment of hypertension with the ACE inhibitor (Cilazapril). Ann Nucl Med 2000;14:353-60.
Schindler T, Schelbert H, Quercioli A, Dilsizian V. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. J Am Coll Cardiol Imaging 2010;3:623-40.
Acknowledgments
The authors would like to thank N. M. T. Jorge Albarrán and N. M. T. Andrés Sanabria for sharing their knowledge and expertise during the acquisition of the PET studies.
Conflict of interest
The authors would like to deny any conflict of interest. The authors of this article disclaim that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Alexánderson, E., Jácome, R., Jiménez-Santos, M. et al. Evaluation of the endothelial function in hypertensive patients with 13N-ammonia PET. J. Nucl. Cardiol. 19, 979–986 (2012). https://doi.org/10.1007/s12350-012-9584-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12350-012-9584-z